Trinity Biotech (TRIB) Competitors $0.74 +0.04 (+5.35%) Closing price 07/16/2025 03:59 PM EasternExtended Trading$0.72 -0.02 (-2.66%) As of 09:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRIB vs. VTVT, ARTV, ALGS, AVTX, JSPR, IPSC, ZIVO, DTIL, SNTI, and RNXTShould you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include vTv Therapeutics (VTVT), Artiva Biotherapeutics (ARTV), Aligos Therapeutics (ALGS), Avalo Therapeutics (AVTX), Jasper Therapeutics (JSPR), Century Therapeutics (IPSC), ZIVO Bioscience (ZIVO), Precision BioSciences (DTIL), Senti Biosciences (SNTI), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry. Trinity Biotech vs. Its Competitors vTv Therapeutics Artiva Biotherapeutics Aligos Therapeutics Avalo Therapeutics Jasper Therapeutics Century Therapeutics ZIVO Bioscience Precision BioSciences Senti Biosciences RenovoRx vTv Therapeutics (NASDAQ:VTVT) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings. Is VTVT or TRIB more profitable? vTv Therapeutics has a net margin of 0.00% compared to Trinity Biotech's net margin of -68.48%. Trinity Biotech's return on equity of 0.00% beat vTv Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets vTv TherapeuticsN/A -121.46% -46.75% Trinity Biotech -68.48%N/A -32.44% Which has stronger earnings and valuation, VTVT or TRIB? vTv Therapeutics has higher earnings, but lower revenue than Trinity Biotech. vTv Therapeutics is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiovTv Therapeutics$1.02M53.14-$18.46M-$3.01-5.64Trinity Biotech$61.56M0.22-$31.79M-$2.93-0.25 Which has more risk & volatility, VTVT or TRIB? vTv Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Does the media favor VTVT or TRIB? In the previous week, vTv Therapeutics had 1 more articles in the media than Trinity Biotech. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for Trinity Biotech. vTv Therapeutics' average media sentiment score of 1.89 beat Trinity Biotech's score of 1.87 indicating that vTv Therapeutics is being referred to more favorably in the media. Company Overall Sentiment vTv Therapeutics Very Positive Trinity Biotech Very Positive Do institutionals and insiders have more ownership in VTVT or TRIB? 17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 4.2% of vTv Therapeutics shares are held by company insiders. Comparatively, 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend VTVT or TRIB? vTv Therapeutics currently has a consensus target price of $35.50, suggesting a potential upside of 108.95%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe vTv Therapeutics is more favorable than Trinity Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryvTv Therapeutics and Trinity Biotech tied by winning 8 of the 16 factors compared between the two stocks. Get Trinity Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRIB vs. The Competition Export to ExcelMetricTrinity BiotechMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.76M$10.28B$5.51B$9.31BDividend YieldN/A2.06%4.25%4.09%P/E Ratio-0.2516.9728.1819.72Price / Sales0.2229.19439.19110.06Price / CashN/A22.2335.5357.53Price / Book-0.383.598.235.67Net Income-$31.79M$233.40M$3.23B$257.51M7 Day Performance-4.27%-3.84%-0.61%-0.16%1 Month Performance22.50%3.36%6.63%9.89%1 Year Performance-74.49%-18.22%27.07%15.08% Trinity Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRIBTrinity Biotech1.1547 of 5 stars$0.74+5.3%N/A-73.6%$12.76M$61.56M-0.25480Positive NewsGap UpVTVTvTv Therapeutics1.6164 of 5 stars$16.71-1.8%$35.50+112.4%-30.3%$53.31M$1.02M-5.559News CoveragePositive NewsARTVArtiva Biotherapeutics2.8493 of 5 stars$2.18+6.9%$17.80+716.5%N/A$53.11M$250K0.0081Positive NewsALGSAligos Therapeutics4.1607 of 5 stars$8.69+3.9%$70.00+705.5%-34.0%$53.10M$3.94M-0.5090AVTXAvalo Therapeutics3.1388 of 5 stars$4.90+2.5%$30.00+512.2%-60.7%$53.06M$441K0.0040JSPRJasper Therapeutics3.707 of 5 stars$3.47-1.1%$29.75+757.3%-84.5%$52.13MN/A-0.6620Analyst RevisionIPSCCentury Therapeutics3.2882 of 5 stars$0.60-0.1%$4.20+600.1%-81.8%$51.69M$114.90M-2.07170ZIVOZIVO BioscienceN/A$13.50flatN/A+59.6%$51.53M$15.85K-2.7710Gap UpDTILPrecision BioSciences4.2179 of 5 stars$4.64+4.3%$47.00+912.9%-56.5%$51.46M$68.70M-2.31200Gap DownSNTISenti Biosciences2.304 of 5 stars$1.97-7.5%$8.50+331.5%-36.5%$51.38MN/A-0.184High Trading VolumeRNXTRenovoRx2.2525 of 5 stars$1.40+8.9%$7.25+417.9%+4.0%$51.20M$240K-3.506Positive News Related Companies and Tools Related Companies vTv Therapeutics Competitors Artiva Biotherapeutics Competitors Aligos Therapeutics Competitors Avalo Therapeutics Competitors Jasper Therapeutics Competitors Century Therapeutics Competitors ZIVO Bioscience Competitors Precision BioSciences Competitors Senti Biosciences Competitors RenovoRx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRIB) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trinity Biotech PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Trinity Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRIB Stock Alerts